Should I Buy KROS Stock in 2026?
Data-driven analysis and honest assessment for Keros Therapeutics Inc
Current Price: $11.67P/E: 5.1
Decision Score
Hold
Based on 6 fundamental factors
Score Breakdown:
Very low P/E of 5.1 suggests undervaluation
Declining -0%
Thin margins (0% net)
Financial health data limited
Excellent FCF yield of 14.2%
No recent insider activity
Key Investment Metrics
Current Price
$11.67
P/E Ratio
5.07
Revenue Growth
-0.9%
Profit Margin
0.4%
Market Cap
$0.4B
Dividend Yield
None
How KROS Compares to Competitors
Understanding how KROS stacks up against peers helps inform your investment decision.
How KROS Compares to Peers
Upcoming Events for KROS
+5 Reasons TO Buy KROS
1. Attractively valued at 5.1x earnings
strongA P/E ratio of 5.1 is below the market average of ~20x, suggesting the stock may be undervalued.
2. High free cash flow yield of 14.2%
strongFCF yield above 5% means substantial cash generation for dividends, buybacks, or reinvestment.
-5 Reasons NOT to Buy KROS
1. Thin profit margins of 0.4%
high riskLow margins provide little cushion against cost increases or pricing pressure.
2. Small-cap volatility risk
high riskMarket cap under $2B means higher volatility and lower liquidity.
3. Revenue declining 1%
medium riskShrinking revenue suggests loss of market share or weakening demand. Turnarounds are difficult.
Who Should Buy KROS?
Investment Profile
Risk Level
Very High
Recommended Holding Period
3-5 years
Best For:
- ✓
Value Investors
P/E of 5.1 offers margin of safety
Not Suitable For:
- ✗
Growth Investors
Limited -1% growth may disappoint
- ✗
Income-Focused Retirees
No dividend paid
- ✗
Risk-Averse Investors
Very High risk may cause uncomfortable volatility
- ✗
Large Position Traders
Lower liquidity may impact execution
Consider These Alternatives
If you're interested in KROS, compare these Health Care peers:
Pro tip: Compare KROS directly with competitors using our comparison tool to see which stock better fits your criteria.
Get the Full Picture
Access AI-powered insights, DCF valuations, insider trading data, and real-time analysis for KROS
Frequently Asked Questions
What is KROS stock price today?
KROS (Keros Therapeutics Inc) stock is trading at $11.67 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).
Is KROS stock going up or down today?
KROS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.
Should I buy KROS stock now?
The decision to buy KROS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.
Is KROS a buy, hold, or sell right now?
Our AI-powered analysis provides buy/hold/sell recommendations for KROS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.
Is KROS stock overvalued or undervalued?
KROS currently trades at a P/E ratio of 5.07, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if KROS is fairly priced.
What is KROS's P/E ratio?
KROS has a price-to-earnings (P/E) ratio of 5.07, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.
What is KROS's market cap?
KROS (Keros Therapeutics Inc) has a market capitalization of $0.36 billion, making it a small-cap stock.
What is KROS's price to book ratio?
KROS trades at a price-to-book (P/B) ratio of 0.76, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.
Deep Dive Analysis
Explore comprehensive analysis tools to make an informed decision about Keros Therapeutics Inc
Full Stock Analysis
Complete KROS overview with charts and data
Is KROS Undervalued?
DCF valuation and intrinsic value analysis
Dividend Analysis
Yield, payout ratio, and dividend history
Growth Analysis
Revenue, earnings, and expansion metrics
Financial Health
Debt, liquidity, and balance sheet strength
Price Prediction
2026 forecast and price targets
Stock Forecast
12-month price forecast and analyst targets
Earnings Date
Next earnings date and historical results
Compare Before You Buy
See how KROS stacks up against its competitors
Similar Investment Decisions
Explore investment analyses for stocks similar to Keros Therapeutics Inc
Complete KROS Analysis
Compare KROS With
Disclaimer
This analysis is for informational purposes only and should not be considered financial advice. The decision score and recommendations are based on quantitative factors and do not account for all risks, your personal financial situation, or qualitative factors. Always do your own research and consider consulting with a financial advisor before making investment decisions.